A group, including pharmaceutical companies, academic centres and the Wellcome Trust has launched a two-year initiative to create a map of genetic markers which will be available without charge. The SNP Consortium will seek to identify single nucleotide polymorphisms involved in disease processes so that safer and more effective drugs can be developed.